Table 3.
Clinical outcomes of NSCLC patients with rare EGFR mutations in exon 20 after EGFRi treatment.
| Mutation | Study (Reference) | EGFR mutation(s), n treated with EGFRi | EGFRi used | ORR (%) | DCR (%) | Median PFS, | Median OS, |
|---|---|---|---|---|---|---|---|
| (CR + PR) | (CR + PR + SD) | months (95% CI) |
months (95% CI) |
||||
| Ex 20 insertion | Beau-Faller et al. [41] | Multiple exon 20 insertions, n = 19 | Gefitinib / Erlotinib | 5.0% | 36.0% | 2 (1 - NE) | 9.5 (4 - 15) |
| Naidoo et al. [57] | Multiple exon 20 insertions, n = 11 | Erlotinib | 27.0% | 45.0% | 2.5 | 26 | |
| Xu et al. [40] | Multiple exon 20 insertions, n = 12 | Gefitinib / Erlotinib / Icotinib | 8.3% | 58.3% | 2.00 (0.00 - 5.41) | 16.69 (13.93 - 19.45) | |
| Kate et al. [108] | Multiple exon 20 insertions, n = 7 | Gefitinib / Erlotinib / Afatinib / Osimertinib | 0.0% | 0.0% | 1.9 (0.3-3.5) | NR | |
| Jänne et al. [109] | Multiple exon 20 insertions, n = 5 | Dacomitinib | 20.0%; 1 PR in D770delinsGY patient | 40.0% | 12.4 months PFS in D770delinsGY patient | NR | |
| Yang et al. [9] | Multiple exon 20 insertions, n = 23 | Afatinib | 8.7% | 65.0% | 2.7 (1.8 - 4.2) | 9.2 (4.1 - 14.2) | |
| Sequist et al. [21] | Multiple exon 20 insertions, n = 3 | Neratinib | 0.0% | NR | NR | NR | |
| Robichaux et al. [49] | Multiple exon 20 insertions, n = 44 | Poziotinib | 43.0% confirmed | NR | 5.6 (5.06 - NE) | NR | |
| Jänne et al. [110] | Multiple exon 20 insertions, n = 26 | TAK-788 | 54.0% | 89.0% | NR | NR | |
| S768I | Leventakos et al. [60] | S768I, n = 1 | Erlotinib | PD | 3 | 5 | |
| S768I complex, n = 3 | 33.3% | 100.0% | 6 - 30 months | 23 - 51 months | |||
| Kobayashi & Mitsudomi [8] | S768I, n = 12 | Gefitinib / Erlotinib | 42.0% | 58.0% | NR | NR | |
| S768I complex, n = 18 | 53.0% | 94.0% | NR | NR | |||
| Chiu et al. [39] | S768I, n = 6 | Gefitinib / Erlotinib | 33.3% | 66.7% | NR | NR | |
| S768I + G719X, n = 10 | 50.0% | 100.0% | NR | NR | |||
| Kate et al. [108] | S768I, n = 2 | Erlotinib | 0.0% | 0.0% | 1.0 (NE) | NR | |
| Chen et al. [111] | S768I, n = 3, S768I + L858R, n = 4, | Gefitinib / Erlotinib / Icotinib | 20.0% | 70.0% | 2.7 (NR) | 14.5 (NR) | |
| S768I + ex19del, n = 3 | |||||||
| Yang et al. [9] | S768I single, n = 1, + S768I complex, n = 7 | Afatinib | 100.0% | 100.0% | 14.7 (2.6 - NE) | NE (3.4 - NE) | |
| Ahn et al. [112] | S768I n = 8 | Osimertinib | 37.5% | NR | NR | NR | |
Legend: EGFRi, EGFR inhibitor; ORR, objective response rate; CR, complete response; PR, partial response; DCR, disease control rate; SD, stable disease; PD, progressive disease; PFS, progression-free survival; CI, confidence interval; OS, overall survival; NR, not reported; NE, not estimable.